Real-world Study of Dedifferentiated Liposarcoma Patients in China

Completed

• Conditions: Dedifferentiated Liposarcoma

• Registration Number: NCT06115681
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-10-27
• Study First Submitted QC: 2023-10-30
• Study First Posted: 2023-11-03
• Study Start: 2024-03-13
• Status Verified: 2024-05
• Primary Completion: 2024-05-15
• Study Completion: 2024-05-15
• Last Update Submitted: 2024-05-15
• Last Update Posted: 2024-05-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1390

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cohort 1: Overall survival	Up to 10 years	Overall survival (OS) as an event for each patient in Cohort 1 will be defined as the date of death minus the index date or the start day of each line of therapy (LOT). For patients with no record of death, OS will be censored at the last activity date before the end of the study period.

Secondary Outcome Measures

Name	Time	Method
Cohort 1, Cohort 2: Number of treatments with drugs classified as steroid therapy	Up to 10 years
Cohort 1, Cohort 2: Survival after initial diagnosis	Up to 10 years	Survival after initial diagnosis for each patient will be defined as the date of death minus the date of initial diagnosis.; For patients with no record of death, survival after initial diagnosis will be censored at the last activity date before the end of the study period.
Cohort 1, Cohort 2: Number of treatments with drugs classified as concurrent immunosuppressant therapy	Up to 10 years
Cohort 1, Cohort 2: Number of treatments with drugs classified as hormone replacement therapy	Up to 10 years
Cohort 1, Cohort 2: Total number of treatment lines	Up to 10 years
Cohort 1, Cohort 2: First line (1L) of therapy by treatment type	Up to 10 years
Cohort 1, Cohort 2: Second line (2L) of therapy by treatment type	Up to 10 years
Cohort 1, Cohort 2: Third line (3L) of therapy by treatment type	Up to 10 years

Trial Locations

Locations (1)

Beijing Jishuitan hospital; 🇨🇳 Beijing, China